Chris Mysko

chrismysko.bsky.social

09 February 2026 15:28

Delighted to share the evolution of @torchuk.bsky.social and our lessons learnt as a road map 🗺️ 🏥 Such a pleasure to work with talented colleagues across the UK to shape this and prime our project pipeline to improve outcomes in liver disease doi.org/10.1136/flga... #liversky #gastrosky #EVADE

damienleith.bsky.social

16 December 2025 10:46

Our editorial in Hepatology about the FMO (fibrotic/ at-risk MASH in obesity) score. Developed to identify At-risk MASH. Validated in 4 external cohort. It uses ALT, AST, triglycerides and HDL and is able to rule-our At-risk MASH with a NPV of 0.97 and predicts LRE. journals.lww.com/hep/citation...

Chris Mysko

chrismysko.bsky.social

12 December 2025 15:03

📢 Final push to get your hospital site registered for #EVADE ✊🏼 Shout out to Scotland who are punching north of the border! 📈 Early trajectory folded in to explore relationship with outcomes from acute decompensation of #cirrhosis #liversky #gastrosky @britsocgastro.bsky.social

mattiasmandorfer.bsky.social

05 October 2025 10:07

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s) 👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3 🖇️ for explanation: authors.elsevier.com/sd/article/S...

Chris Mysko

chrismysko.bsky.social

26 September 2025 06:21

📢 Delighted to share our next @torchuk.bsky.social project #EVADE is LIVE! 📢 An important topic and our first prospective audit, so should be fun 🏥🩺🔦 Project dashboard: redcap.link/evade #liversky #gastrosky @britsocgastro.bsky.social @britishlivertrust.bsky.social @gutscharityuk.bsky.social